Evidence map›Paper›PMID 36635979›Full record

ArticleThoracic cancer2023

C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study.

Kei Sonehara, Ryota Ozawa, Mineyuki Hama, Shuhei Nozawa, Toshihiko Agatsuma, Kenichi Nishie, Akane Kato, Akemi Matsuo, Taisuke Araki, Masamichi Komatsu and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kei SoneharaFirst Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.ORCID 0000-0001-9810-4016
Ryota OzawaDepartment of Respiratory Medicine, Nagano Red Cross Hospital, Nagano, Japan.
Mineyuki HamaDepartment of Respiratory Medicine, Suwa Red Cross Hospital, Suwa, Japan.
Shuhei NozawaDepartment of Respiratory Medicine, Nagano Municipal Hospital, Nagano, Japan.
Toshihiko AgatsumaDepartment of Respiratory Medicine, National Hospital Organization Shinshu Ueda Medical Center, Ueda, Japan.
Kenichi NishieDepartment of Respiratory Medicine, Iida Municipal Hospital, Iida, Japan.
Akane KatoDepartment of Respiratory Medicine, Ina Central Hospital, Ina, Japan.
Akemi MatsuoDepartment of Respiratory Medicine, Minaminagano Medical Center, Shinonoi General Hospital, Nagano, Japan.
Taisuke ArakiFirst Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.ORCID 0000-0002-8033-868X
Masamichi KomatsuFirst Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Kazunari TateishiFirst Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.ORCID 0000-0003-4641-640X
Masayuki HanaokaFirst Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCombination immunotherapy (immune checkpoint inhibitors and cytotoxic anticancer agents) is widely used as first-line treatment for advanced non-small cell lung cancer (NSCLC). However, the therapeutic effect of combination immunotherapy has not been fully investigated. C-reactive protein, performance status, lactate dehydrogenase, albumin, and derived neutrophil-to-lymphocyte ratio (C-PLAN) are useful biomarkers for predicting the prognosis of NSCLC; however, there are no reports examining the C-PLAN index, which combines these five factors in a single prognostic factor.

methodsWe retrospectively collected data from 178 patients with previously untreated advanced NSCLC who received combination immunotherapy at multicenter institutions in Nagano Prefecture between December 2018 and April 2022. We investigated the utility of the C-PLAN index as a prognostic factor using Cox regression analysis and correlated it with survival.

resultsThe good and poor C-PLAN index groups included 85 and 93 patients, respectively. The good C-PLAN index group had a longer median progression-free survival (PFS) (10.7 vs. 6.0 months; p = 0.022) and overall survival (OS) (25.3 vs. 16.5 months; p = 0.003) than the poor C-PLAN index group. The C-PLAN index was an independent favorable prognostic factor that correlated with PFS and OS in multivariate analysis. The good C-PLAN index group had a higher proportion of never-smokers (16.5 vs. 4.3%; p = 0.007) and stage III disease/postoperative recurrence (32.9 vs. 15.1%; p = 0.005) than the poor C-PLAN index group.

conclusionThe C-PLAN index is a useful prognostic factor for patients with previously untreated advanced NSCLC undergoing combination immunotherapy.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmunotherapyNeoplasm Recurrence, LocalPrognosisRetrospective Studiescombination immunotherapyC-PLAN indexnon-small cell lung cancerprognostic factor

Identifiers

PMID36635979
PMCPMC9968595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.